Companies › Rhythm Pharmaceuticals
2 active drug programs in 5 registered trials: 2 Phase 3, 1 Phase 1, 1 Phase 2, 1 Phase 4; Metabolic and endocrine; next expected readout Mar 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Setmelanotide Melanocortin receptor 4 agonist | MC4R | Phase 3 | Hypothalamic Obesity; Prader-Willi Syndrome; Bardet Biedl Syndrome (BBS) | Mar 2027 |
| RM-718 MC4R (melanocortin 4 receptor) agonist | MC4R | Phase 1 | Hypothalamic Obesity | May 2027 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT06760546 | Setmelanotide | Phase 3 | Hypothalamic Obesity | Metabolic and endocrine | Mar 2027 |
| NCT05774756 | Setmelanotide | Phase 3 | Hypothalamic Obesity | Metabolic and endocrine | Apr 2027 |
| NCT06239116 | RM-718 | Phase 1 | Hypothalamic Obesity | Metabolic and endocrine | May 2027 |
| NCT06772597 | Setmelanotide | Phase 2 | Prader-Willi Syndrome | Metabolic and endocrine | Oct 2027 |
| NCT07674290 | Setmelanotide | Phase 4 | Bardet Biedl Syndrome (BBS) | Metabolic and endocrine | Dec 2030 |
Cash and short-term investments of $321m on 2026-09-30; operating cash outflow about $76m a year; runway about 51 months at that burn, to Dec 2030; 3 of 3 coming phase 2-3 readouts fall inside that runway
Press releases filed as 8-K in the last year:
Held by 13 of the 39 life-science funds Phaseline follows through their 13F filings. Who holds what.
MBX Biosciences Amylyx Pharmaceuticals Viking Therapeutics Kailera vTv Therapeutics
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.